Medical/Pharmaceuticals
Ascentage Pharma Announces 2022 Interim Results
SUZHOU, China and ROCKVILLE, Md. , Aug. 26, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its 2022 interim results. During the reporting p...
2022-08-27 00:47
15663
First approval of Cadonilimab (PD-1/CTLA-4 bispecific) published in Drugs, a peer-reviewed medical journal
HONG KONG, Aug. 26, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company committed to the research, development, manufacturing and commercialization of either first-in-class or best-in-class therapies, announced a review article featuring onCadonilimab, a first-in-cla...
2022-08-26 20:00
3785
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
Second region now open for enrolment for rare, rapidly progressive, neurodegenerative disease MELBOURNE, Australia and SAN FRANCISCO, Aug. 25, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing diseas...
2022-08-25 19:25
3480
Tigermed Reports 2022 Interim Result with Strong Financial Growth
HANGZHOU, China, Aug. 25, 2022 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its interi...
2022-08-25 19:05
4760
111, Inc. Announces Second Quarter 2022 Unaudited Financial Results
SHANGHAI, Aug. 25, 2022 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the second quar...
2022-08-25 14:18
3865
Alpha Biopharma Announces Completion of its EVEREST Phase II/III Clinical Study of Zorifertinib in Non-Small Cell Lung Cancer Patients with Central Nervous System Metastases
* Zorifertinib is a next generation EGFR-TKI with full Blood Brain Barrier penetration targeting EGFRm+ NSCLC patients with CNS metastases * Top-line data from the study are expected around the end of 2022 SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- Alpha Biopharma, a developer of innovative drugs...
2022-08-25 10:00
2315
Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment Commercialization Strategy
SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, issued its 2022 semi-annual report today. As disclosed in...
2022-08-25 00:46
3318
CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline
SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, has announced the 2022 Interim Results. Business Highlights * CT053: comple...
2022-08-24 20:50
3823
Jacobio Pharma Announces 2022 Interim Results
Investment in R&D increased 26.3% to RMB 221 million. Recorded revenue was RMB 54.7 million. Global development of KRAS G12C inhibitor and other clinical stage drug candidates accelerated. Development started in new pre-clinical stage drug candidates, such as iADC (immunostimulatory antibody-dr...
2022-08-24 00:32
3983
I-Mab Announces Share Purchase Plans by the Company and the Senior Management
GAITHERSBURG, Md. and SHANGHAI, Aug. 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it plans to implement share repurchases...
2022-08-23 21:13
4008
Clarity advances to cohort 3 of the CL04 trial of SARTATE™ in paediatric neuroblastoma
Highlights * Cohort 2 completed in participants with neuroblastoma who received therapy with67Cu SARTATE™ at a dose of 175MBq/kg body weight * No Dose Limiting Toxicities (DLTs) have been reported in cohort 1 and cohort 2 * Safety Review Committee (SRC) has recommended the trial continues w...
2022-08-23 21:04
3697
BIORCHESTRA appointed Dr. Gabriel Helmlinger (Ph.D., DABT) as Head of Translational and Clinical Pharmacology, Toxicology
BOSTON, Mass., Aug. 23, 2022 /PRNewswire/ -- BIORCHESTRA, headquartered in Daejeon,South Korea, appointed Dr. Gabriel Helmlinger (Ph.D., D.A.B.T.) as Vice-President, Head of Translational & Clinical Pharmacology, Toxicology. Dr. Helmlinger brings 25 years of drug research and clinical development...
2022-08-23 20:00
2765
AESOP Technology Wins Coveted Place in Mayo Clinic Platform_Accelerate Program to Build Better AI Model for Healthcare
SAN FRANCISCO, Aug. 22, 2022 /PRNewswire/ -- AESOP Technology
2022-08-23 00:00
3187
AVELOS THERAPEUTICS ANNOUNCES $8 MILLON SERIES A FUNDING ROUND
Seoul-Based Biotechnology Company to Use Financing for Expanding Oncology Drug Discovery and Development SEOUL, South Korea, Aug. 22, 2022 /PRNewswire/ -- Innovative biotechnology company specializing in new drug discovery and development, Avelos Therapeutics, has received a glowing endorsement ...
2022-08-22 20:00
2543
Ubie, Japanese Health-tech Startup, Raises $26.2 Million in Series C, $59.8 Million in Total
- Bringing Unprecedented Medical Experience by Strengthening Partnerships with Pharmaceutical Companies inJapan and U.S. to Build Medical Data Platform - TOKYO and SINGAPORE, Aug. 22, 2022 /PRNewswire/ -- Ubie, Inc., a healthcare AI startup with the mission "To develop a healthcare guide for ever...
2022-08-22 14:00
3080
Biosion, Inc. Appoints Steven Knapp, Pharm.D. as Chief Regulatory & Quality Officer
NEWARK, Del. and NANJING, China, Aug. 22, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a leading global R&D biotechnology company, today announced the appointment ofSteven Knapp, PharmD., as Chief Regulatory & Quality Officer. In this position, he is responsible for the strategic leadership...
2022-08-22 13:00
2275
I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022
- Major updates will focus on global clinical development of core assets, upcoming milestones and financial results - The Company will update on potential implementation of a comprehensive share purchase program by the Company and current shareholders - Conference Calls Scheduled at 7:00 a.m....
2022-08-19 21:00
2833
AIRS Medical Raises $20M in Series B Funding
SEOUL, South Korea, Aug. 19, 2022 /PRNewswire/ -- AIRS Medical, a healthcare startup based inSouth Korea and a member of the Born2Global Centre, recently announced that it has raised approximately$20M in Series B funding. The round of Series B funding welcomed new investors Q Capital Partners and...
2022-08-19 21:00
3144
World's First CAR-T for NMOSD Treatment, IASO Biotherapeutics' Equecabtagene Autoleucel, Receives IND Approval by NMPA
SHANGHAI, NANJING, China and SAN JOSE, Calif., Aug. 19, 2022 /PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, announced today that the Center for Drug ...
2022-08-19 18:41
2422
J INTS BIO successfully held its 1st International Advisory Board Meeting for its Novel Oral 4th Generation EGFR TKI (JIN-A02) in Vienna, Austria during WCLC
SEOUL, South Korea, Aug. 19, 2022 /PRNewswire/ -- J INTS BIO announced that it held its 1st International Advisory Board Meeting for its Novel Oral 4th Generation EGFR-TKI 'JIN-A02' on the sideline of the 2022 IASLC World Conference on Lung Cancer held inVienna, Austria, on 7th August. This follo...
2022-08-19 16:00
1513
Week's Top Stories
Most Reposted
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
[Picked up by 327 media titles]
2026-08-05 11:34
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 313 media titles]
2026-08-07 22:30Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
[Picked up by 301 media titles]
2026-08-06 15:10
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
[Picked up by 298 media titles]
2026-08-04 07:00
Vitafoods Asia Announces Strategic Move to Kuala Lumpur for 2027 Edition
[Picked up by 294 media titles]
2026-08-04 14:30
Most Read
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
2026-08-04 07:00
17251
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
2026-08-05 11:34
15886
Gene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' Academy
2026-08-04 06:00
13693
Vitafoods Asia Announces Strategic Move to Kuala Lumpur for 2027 Edition
2026-08-04 14:30
13352